Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    P1.11 - Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
    • +

      P1.11-01 - Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung

      Presenter: Hye Ryun Kim

      • Abstract

      Loading...

    • +

      P1.11-02 - Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C

      Presenter: Baohui Han

      • Abstract

      Loading...

  • +

    P1.12 - Management of Lung Cancer in the Era of COVID-19

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Management of Lung Cancer in the Era of COVID-19
    • +

      P1.12-01 - Lung Cancer Screening in the COVID-19 Era: Understanding Program-Level Impact

      Presenter: Andrew Ciupek

      • Abstract

      Loading...

    • +

      P1.12-02 - The Impact of COVID-19 on Quality of Care for Lung Cancer - Analyses of Prospective Clinical Data from The EnRICH Cohort

      Presenter: Bea Brown

      • Abstract

      Loading...

    • +

      P1.12-03 - Computed Tomography-based Artificial Intelligence System in the Diagnosis of COVID-19

      Presenter: Yusuf Kahya

      • Abstract

      Loading...

    • +

      P1.12-04 - The FLARE score and circulating neutrophils are associated with poor Covid-19 outcomes in patients with thoracic cancers

      Presenter: Laura Mezquita

      • Abstract

      Loading...

    • +

      P1.12-05 - Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st wave)

      Presenter: Yu Zhi Zhang

      • Abstract

      Loading...

  • +

    P1.13 - Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical
    • +

      P1.13-01 - Preoperative Chemotherapy Induces Epithelial-Mesenchymal Transition Which Reduces Survival After Surgery for Mesothelioma

      Presenter: Luigi Ventura

      • Abstract

      Loading...

    • +

      P1.13-02 - Quantitative Assessment Using MR in Malignant Pleural Mesothelioma

      Presenter: Ritu Gill

      • Abstract

      Loading...

  • +

    P1.14 - Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical
    • +

      P1.14-01 - Transcriptomic Analysis of Malignant Pleural Mesothelioma (MPM) Reveals Insights for Basic Research and Preclinical Testing

      Presenter: Alexander Laure

      • Abstract

      Loading...

    • +

      P1.14-02 - Implantable Cytokine Factories for Eradication of Malignant Pleural Mesothelioma (MPM) Tumors in Mice

      Presenter: Amanda Nash

      • Abstract

      Loading...

    • +

      P1.14-03 - Characterization of Tumor Immune Microenvironment and Its Prognostic Value in Patients with Surgically Resected Thymic Epithelial Tumors

      Presenter: HaoJie Si

      • Abstract

      Loading...

    • +

      P1.14-04 - Silencing ADAR1 Abrogates Mesothelioma Tumorigenicity

      Presenter: Robert Kratzke

      • Abstract

      Loading...

    • +

      P1.14-05 - TROP2 Expression and SN38 Antitumor Activity in Malignant Pleural Mesothelioma Cells

      Presenter: Luca Hegedüs

      • Abstract

      Loading...

  • +

    P1.15 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      P1.15-01 - Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy With Radiomics

      Presenter: Alberto Traverso

      • Abstract

      Loading...

    • +

      P1.15-02 - Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors

      Presenter: Claudia Proto

      • Abstract

      Loading...

    • +

      P1.15-03 - Clinical Outcomes Among Patients With Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity

      Presenter: Federica Pecci

      • Abstract

      Loading...

    • +

      P1.15-04 - Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer

      Presenter: Giulia Mazzaschi

      • Abstract

      Loading...

    • +

      P1.15-05 - Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)

      Presenter: Martin Reck

      • Abstract

      Loading...

    • +

      P1.15-06 - Immune-Checkpoint Inhibitors-Related Colitis in Advanced Non-small Cell Lung Cancer Patients: A Real-World Analysis

      Presenter: Martina Lorenzi

      • Abstract

      Loading...

    • +

      P1.15-07 - Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1

      Presenter: Melina Elpi Marmarelis

      • Abstract

      Loading...

    • +

      P1.15-08 - Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer

      Presenter: Michael Boyer

      • Abstract

      Loading...

    • +

      P1.15-09 - First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.

      Presenter: Mariano Provencio

      • Abstract

      Loading...

    • +

      P1.15-10 - Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada

      Presenter: Sze Wah Samuel Chan

      • Abstract

      Loading...

    • +

      P1.15-11 - Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study

      Presenter: Myung-Ju Ahn

      • Abstract

      Loading...

    • +

      P1.15-12 - Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

      Presenter: Saadettin Kilickap

      • Abstract

      Loading...

    • +

      P1.15-13 - Immune Escape Mechanisms Mediated by B-Catenin in Non-small Cell Lung Cancer

      Presenter: Satoshi Muto

      • Abstract

      Loading...

  • +

    P1.16 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      P1.16-01 - Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

      Presenter: Byoung Chul Cho

      • Abstract

      Loading...

    • +

      P1.16-02 - Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale

      Presenter: Laura Mezquita

      • Abstract

      Loading...

    • +

      P1.16-03 - Managing Cardiotoxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

      Presenter: Luis Raez, MD, FACP, FCCP

      • Abstract

      Loading...

    • +

      P1.16-04 - Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors

      Presenter: Niels Reinmuth

      • Abstract

      Loading...